In its attempt to provide treatments for Covid-19 patients, American biopharma firm FibroGen has chosen to tackle the infection slightly differently to many of its peers in the industry.
Antivirals such as Gilead’s remdesivir and anti-inflammatory medicines like the chloroquine drug currently being taken by US president Donald Trump have drawn much of the mainstream media attention regarding coronavirus treatments thus far.
But FibroGen is instead trying to treat the symptoms of pneumonia — often seen in severely ill Covid-19 patients — using its antibody drug pamrevlumab.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData